Replimune REPL
NASDAQ REPL
$13.07 -0.38 (-2.83%)
At close: Oct 2, 2026 · 4:00 PM EDT

Replimune (REPL) Asset Writedowns and Impairment (2026)

Updated

Replimune's Asset Writedowns and Impairment was $108,000 in fiscal Q1 2027 (quarter ended Jun 30, 2026).

Analysis

Replimune (REPL) Asset Writedowns and Impairment (2026) Analysis & Trends

For FY2026 (ended Mar 31, 2026), Asset Writedowns and Impairment at Replimune came in at $188,000.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 Replimune 1.11 Bn 1.11 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 108,000.00
API Access

Replimune Asset Writedowns and Impairment API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=asset-writedowns-and-impairment&ticker=REPL&period=max&api_key=YOUR_API_KEY